New York State Common Retirement Fund increased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 26.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,811,743 shares of the company's stock after acquiring an additional 585,420 shares during the quarter. New York State Common Retirement Fund owned about 0.15% of Kenvue worth $60,031,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of KVUE. State Street Corp raised its stake in shares of Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares in the last quarter. Holocene Advisors LP increased its stake in Kenvue by 75.5% during the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company's stock valued at $321,194,000 after purchasing an additional 5,975,392 shares in the last quarter. M&G PLC increased its stake in Kenvue by 538.0% during the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company's stock valued at $99,847,000 after purchasing an additional 3,660,730 shares in the last quarter. Finally, FMR LLC increased its stake in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Analyst Upgrades and Downgrades
KVUE has been the topic of a number of recent analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday, January 17th. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group cut their price target on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has a consensus rating of "Hold" and an average target price of $23.00.
Read Our Latest Stock Analysis on Kenvue
Kenvue Stock Performance
NYSE KVUE traded up $0.86 during mid-day trading on Friday, reaching $23.25. 16,393,276 shares of the stock were exchanged, compared to its average volume of 13,506,300. The business's 50 day moving average is $21.29 and its 200-day moving average is $22.14. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market capitalization of $44.58 billion, a P/E ratio of 43.88, a P/E/G ratio of 2.61 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
